Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.62 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | MYC | P01106 | 10/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23183031 | 0.88 | GBA1 (0.50) | GBA1CCR1CCR5CCR8HDAC6 | |
| SCHEMBL21388440 | 0.88 | HCAR3 (0.50) | GBA1CCR1CCR5CCR8HDAC6 | |
| SCHEMBL11567147 | 0.85 | GBA1 (0.47) | GBA1AOC3KMT2A | |
| SCHEMBL20056973 | 0.83 | HCAR3 (0.57) | GBA1CCR1CCR5CCR8HDAC6 | |
| SCHEMBL21241060 | 0.82 | GBA1 (0.45) | GBA1CCR1CCR5CCR8HDAC6 | |
| SCHEMBL18937028 | 0.82 | GBA1 (0.45) | GBA1CCR1CCR5CCR8HDAC6 | |
| SCHEMBL8278724 | 0.81 | CCR1 (0.48) | GBA1CCR1CCR5CCR8HDAC6 | |
| SCHEMBL12394221 | 0.80 | HCAR3 (0.46) | GBA1CCR1CCR5CCR8HDAC6 | |
| SCHEMBL11567387 | 0.80 | GBA1 (0.48) | GBA1KDM4EKMT2A | |
| SCHEMBL19417994 | 0.79 | NOS3 (0.43) | GBA1CCR1CCR5CCR8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| EP-3436446-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230125712-A1 | SELF-LUMINOUS DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2023-04-27 | — | — | US | disclosed |
| EP-4066834-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | Infinity Pharmaceuticals, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-3305778-B1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-19 | — | — | EP | disclosed |
| EP-3441392-B1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | INTELLIKINE LLC (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3811974-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | Infinity Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20110160232-A1 | CERTAIN CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | INTELLIKINE LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110160232-A1 | CERTAIN CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | INTELLIKINE LLC | 2011-06-30 | — | — | US | disclosed |
| WO-2011008302-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010043000-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009088990-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009046448-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | INTELLIKINE, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| EP-0569701-B1 | Process for preparation of 2-amino-5-methyl-pyridine | BAYER AG (DE) | 2000-09-27 | — | — | EP | disclosed |
| US-5463065-A | Process for the preparation of 2-amino-5-methyl-pyridine | BAYER AKTIENGESELLSCHAFT (DE) | 1995-10-31 | — | — | US | disclosed |
| US-5332824-A | Process for the preparation of 2-amino-5-methyl-pyridine | BAYER AKTIENGESELLSCHAFT (DE) | 1994-07-26 | — | — | US | disclosed |
| EP-0569701-A1 | Process for preparation of 2-amino-5-methyl-pyridine | BAYER AG (DE) | 1993-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | GBA1 1541/4885CCR1 1199/4885CCR5 594/4885 |
| US-11771738-B2 | Endoparasitic depsipeptides | VIP, PREP, VIPR1 | GBA1 381/4885CCR1 692/4885CCR5 1684/4885 |
| US-20110160232-A1 | CERTAIN CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | PIK3CA, PIK3C3, PRKACA | GBA1 702/4885CCR1 3756/4885CCR5 4437/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | GBA1 3052/4885CCR1 2706/4885CCR5 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.